Company news
Georgiamune and Verily Announce Strategic Partnership to Advance Novel Cancer Treatment
Gaithersburg, MD and South San Francisco, CA – Oct. 26, 2023 – Georgiamune, a privately held, clinical stage biotechnology company, and Verily, an Alphabet precision health technology company, today announced a strategic partnership to advance novel therapeutics for patients with cancer.
Georgiamune Inc. Achieves US FDA Clearance for Investigational New Drug (IND) Application and Secures $75 Million in Series A Financing
Gaithersburg, MD, August 09, 2023 - Today, Georgiamune Inc., a privately held, clinical stage biotechnology company, announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for GIM-122, a dual-functioning monoclonal antibody. Furthermore, the company successfully completed a $75M Series A financing, positioning Georgiamune as a promising new biotechnology company in the fields of oncology and autoimmune diseases.
942 Clopper Rd
Gaithersburg, MD 20878
United States
.png)
